Advertisement
Workshop track 3 Workshop: Cardiovascular risk assessment from epidemiology to genetics| Volume 287, e8, August 2019

A Mendelian Randomization Analysis Of Lipoprotein(A) Lowering And Cardiovascular Risk Stratified By Ldl Cholesterol, Gender, And Antiplatelet Therapy: Implications For Clinical Outcome Trials

Published:August 03, 2019DOI:https://doi.org/10.1016/j.atherosclerosis.2019.06.021
A Mendelian Randomization Analysis Of Lipoprotein(A) Lowering And Cardiovascular Risk Stratified By Ldl Cholesterol, Gender, And Antiplatelet Therapy: Implications For Clinical Outcome Trials
Previous ArticleEfficacy and Safety of Bempedoic Acid + Ezetimibe Fixed-Dose Combination in Patients at High CVD Risk and with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy
Next ArticleLipoprotein(A) Predicts Cardiovascular Events In Statin Outcome Trials: Pooled Analysis Of Seven Randomised Controlled Trials
      Background and Aims: Lipoprotein(a) is causally associated with the risk of CVD. Novel therapies that potently and specifically reduce plasma concentration of lipoprotein(a) by up to 70−80% are currently in development. We sought to examine whether the effect of lipoprotein(a) lowering on risk of CVD is modified by LDL cholesterol (LDL-C) level, gender, and antiplatelet therapy to inform the design of clinical outcome trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      Published online: August 03, 2019
      EAS19-0777

      Identification

      DOI: https://doi.org/10.1016/j.atherosclerosis.2019.06.021

      Copyright

      © 2019 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX